argenx SE News

argenx SE | 6-K: Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

Apr 16 06:09 ET

argenx SE | 6-K: argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

Mar 27 06:18 ET

argenx SE | 6-K: argenx Announces Annual General Meeting of Shareholders on May 7, 2024

Mar 27 06:09 ET

argenx SE | 6-K: Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Mar 26 06:09 ET

argenx SE | 20-F: Registration statement / Annual report / Transition report

Mar 21 06:25 ET

argenx SE | 6-K: Annual Report dated March 21, 2024

Mar 21 06:15 ET

argenx SE | 6-K: Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

Mar 8 06:10 ET

argenx SE | 6-K: Report of foreign private issuer (related to financial reporting)

Feb 29 16:17 ET

argenx SE | 6-K: argenx Announces FDA Acceptance of Supplemental Biologics License Application

Feb 20 06:08 ET

argenx SE | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-T. ROWE PRICE ASSOCIATES, INC.(6.2%)

Feb 14 10:16 ET

argenx SE | SC 13G: Statement of acquisition of beneficial ownership by individuals-Artisan Partners Limited Partnership(5.4%),Artisan Investments GP LLC(5.4%), etc.

Feb 12 07:04 ET

argenx SE | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(7.064%),Abigail P. Johnson(7.064%)

Feb 9 08:40 ET

argenx SE | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(6.8%)

Feb 1 13:07 ET

argenx SE | 6-K: argenx Announces Approval of VYVDURA Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

Jan 18 00:00 ET

argenx SE | 6-K: Report of foreign private issuer (related to financial reporting)

Jan 8 00:00 ET

argenx SE | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Dec 20, 2023 06:00 ET

argenx SE | 6-K: Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

Nov 28, 2023 06:01 ET

argenx SE | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Nov 17, 2023 06:01 ET

argenx SE | 6-K: argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Nov 1, 2023 16:01 ET

argenx SE | 6-K: Report of foreign private issuer (related to financial reporting)

Oct 31, 2023 09:14 ET